Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cintredekin besudotox

Drug Profile

Cintredekin besudotox

Alternative Names: hIL13-PE38QQR; IL13-PE38; IL13-PE38QQR; Interleukin-13-PE38QQR immunotoxin; NK 408

Latest Information Update: 21 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institutes of Health (USA)
  • Developer INSYS Therapeutics, Inc; National Institutes of Health (USA); Nippon Kayaku
  • Class Antineoplastics; Drug conjugates; Exotoxins; Immunotoxins; Interleukins
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Anaplastic astrocytoma; Idiopathic pulmonary fibrosis; Glioblastoma; Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Adrenocortical carcinoma; Asthma; Glioma; Pulmonary fibrosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 17 Nov 2014 Insys Therapeutics terminates a phase I/II trial in Adrenocortical carcinoma (metastatic disease, second-line therapy or greater) in USA (NCT01832974)
  • 01 Jul 2011 Insys Therapeutics completes a phase I trial in Malignant glioma (newly diagnosed) in USA (NCT00089427)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top